• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

    5/2/25 4:11:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TTNP alert in real time by email
    DEFA14A 1 titanpharma_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under §240.14a-12

     

    Titan Pharmaceuticals, Inc.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Persons(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    2025 TI T AN PHARMACEUTICALS, INC. Signature Signature, if held jointly Date , 2025. Pleas e sig n exactl y a s you r nam e appear s belo w . Whe n share s ar e hel d b y join t tenants , eac h shoul d sign . Whe n signin g a s attorne y , executo r, administrato r, trustee, guardian , corporat e o f fice r , o r partne r, pleas e giv e ful l titl e a s such. Please mark your votes lik e this X 19730 2 T ita n Pharma Proxy Car d Rev 3 Front CONTRO L NUMBER PROXY TH E BOAR D O F DIREC T OR S RECOMMEND S A VOT E FO R PROPOSAL S 1 , 2 , 3 , 4 AN D 5 , AN D FO R “ TW O YEAR S ” A S TH E FREQUENC Y FO R WHIC H S T OCKHOLDER S WIL L H A V E A VOT E O N EXECUTIV E COMPENS A TIO N . 4 . R A TIFIC A TION OF ENROME LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUN T ANT S FOR THE FISCAL YEAR ENDING DECEMBE R 31 , 2025. 5 . APPRO V A L OF OUR EXECUTIVE COMPENS A TION (S A Y - ON - P A Y). 6 . FREQUENCY OF S A Y - ON - P A Y VOTE. FOL D HER E • D O NO T SE P AR A T E • INSER T I N ENVELOP E PROVIDE D PLEAS E MARK , SIGN , D A T E AN D RETUR N TH E PROXY CAR D PROMPT L Y USIN G TH E ENCLOSE D ENVELOP E . a s if yo u marked , signe d an d returne d you r proxy card . V otes submitte d electronicall y over the Internet mus t be receive d by 1 1 : 5 9 p . m . , Eastern T ime, on Jun e 15 , 2025 . INTERNET ww w .cstproxyvote.com Us e the Internet to vote your prox y . Hav e your prox y card availabl e when you acces s the abov e website . Follow the prompt s to vote your shares. MOBILE VOTING On your Smartphone / T ablet , ope n the QR Reade r an d scan the belo w image. Once the voting site i s displayed , enter your Contro l Numbe r from the proxy card an d vote your shares. MAIL – Mark, sign an d dat e your proxy card an d return i t i n the postage - paid envelop e provided. ELECTION OF DIREC T ORS 1. APPRO V A L O F TH E 2015 PLAN AMENDMEN T . 3. V ot e b y Internet , Smartphon e o r T able t - QUIC K EAS Y IMMEDI A T E - 2 4 Hour s a Da y , 7 Day s a W ee k o r b y Mail Y our Mobile or Internet vot e authorize s the named proxies to vot e you r share s in the sam e manner Nominees: A vraham Ben - Tzvi Brynner Chiam Francisco Osvaldo Flores Garcia Firdauz Edmin Bin Mokhtar Gabriel Loh FOR al l nominees liste d a t lef t (except a s marked to the contrary below) WITHHOLD AUTHORITY to vote for al l nominees liste d a t left INSTRUCTION : T o withhol d authorit y t o vot e fo r an y nominee, writ e th e nominee ’ s nam e i n th e spac e provide d belo w . PLEASE D O NO T RETUR N THE PROXY CARD IF YOU AR E VOTING ELECTRONICAL L Y . YOUR VOTE IS IMPOR T AN T . PLEASE VOTE T OD A Y . FOR AGAINST ABS T AIN FOR AGAINST ABS T AIN FOR AGAINS T ABS T AIN FOR AGAINS T ABS T AIN EVE R Y ONE YEAR EVE R Y TWO YEARS EVE R Y THREE YEARS ABS T AIN APPRO V A L O F TH E ISSUANCE PROPOSA L . 2.

     

     

     

     

    2025 FOL D HER E • D O NO T SE P AR A T E • INSER T I N ENVELOP E PROVIDE D THIS PROXY IS SOLICITED ON BEHAL F OF THE BOAR D OF DIREC T ORS PROXY FOR THE ANNUA L MEETING OF S T OCKHOLDERS OF TI T A N PHARMACEUTICALS, INC. T O B E HEL D ON JUN E 16 , 2025 The undersigne d appoint s Cha y W ee i Jye an d Brynner Chiam , an d eac h o f them, attorney s and agent s wit h full powe r o f substitution, i s hereb y authorize d to vote al l o f the shares o f common stock o f T ita n Pharmaceuticals, Inc . (the “Company”) whic h the undersigne d woul d b e entitle d to vote, if personall y present , a t the upcomin g Annual Meeting o f Stockholders o f the Compan y scheduled to be held at the offices of Olshan Frome W olosky LL P , located at 1325 A venue of the Americas, 15 th Floo r , New Y ork, New Y ork 10019 on Monda y , June 16 , 2025 at 9 : 00 a . m . (EST) (including any adjournments o r postponement s thereof an d an y meeting called i n lie u thereof, the “Annual Meeting”) . The und ersigned hereb y revokes an y prox y o r proxie s heretofor e give n an d acknowledge s receipt o f a copy o f the Notic e o f Meeting an d Proxy Statement an d a copy o f the Company ’ s Annual Repor t on Form 10 - K (without exhibits) for the fiscal year ended December 31 , 2024 . IF N O DIRECTIO N IS INDIC A TED WITH RESPEC T T O THE PROPOSALS ON THE REVERSE , THIS PROXY WILL B E VOTED “FOR AL L NOMINEES ” WITH RESPEC T T O PROPOSAL 1 AN D “FOR” PROPOSALS 2 , 3 , 4 AN D 5 AN D FOR “EVE R Y TWO YEARS” A S THE FREQUENCY FOR WHICH S T OCKHOLDERS WILL H A VE A VOTE ON EXECUTIVE COMPENS A TION . IMPOR T AN T : PLEASE SIGN, D A TE AN D MAIL THIS PROXY CAR D PROMPT L Y! CONTINUE D AN D T O B E SIGNED ON REVERS E SIDE 19730 2 T ita n Pharma Proxy Car d Rev 3 Back Important Notic e Regardin g the A vailabilit y of Proxy Materials for the Annua l Meeting of Stockholders Of T itan Pharmaceuticals, Inc. to be held on Jun e 16 , 2025 The proxy statemen t is availabl e at https://ww w .cstprox y .com/titanpharm/am2025

     

     

    Get the next $TTNP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTNP

    DatePrice TargetRatingAnalyst
    More analyst ratings